Many clinical trials of mRNA-based drugs or vaccines have failed to successfully pass Phase I or Phase II. The reasons behind this are various, including low efficacy of candidate drugs and lower-than-expected clinical risk/treatment benefit profiles. Preclinical safety assessments aim to identify well-tolerated and efficacious LNP-mRNA formulations, and when toxicity is observed, in vivo, in vitro and ex vivo experiments aim to understand the underlying mechanisms and, ideally, improve the…

Traditional immunoassays based on the format of 96-well microtiter plates are widely used in analytical laboratories and have become increasingly automated with the introduction of robotics technology in recent years, thereby enhancing assay throughput. Most clinical analyzers essentially operate as “stand-alone laboratories,” featuring precise, accurate, and highly reproducible programmatic liquid handling, sample addition, and washing steps. However, aside from cost, the size limitations of these…